Establishment of the first World Health Organization

International Standard for human parvovirus B19 DNA nucleic

acid amplification techniques by Saldanha, J. et al.
 24
 
Vox Sanguinis
 
 (2002) 
 
82
 
, 24–31
 
ORIGINAL PAPER
 
©
 
 2002 Blackwell Science
 
Blackwell Science LtdEstablishment of the first World Health Organization 
International Standard for human parvovirus B19 DNA nucleic 
acid amplification techniques
 
J. Saldanha
 
1
 
, N. Lelie
 
2
 
, M. W. Yu
 
3
 
, A. Heath
 
4
 
 & the B19 Collaborative Study Group
 
*
 
1
 
Division of Virology, National Institute for Biological Standards and Controls, South Mimms, Herts., UK
 
2
 
CLB, Plesmanlaan 125, Amsterdam, the Netherlands
 
3
 
Division of Hematology, CBER/FDA, Bethesda, Maryland, USA
 
4
 
Informatics Division, National Institute for Biological Standards and Controls, South Mimms, Herts., UK
 
Background and Objectives
 
A collaborative study, involving 26 laboratories from 14
countries, was carried out in order to establish a World Health Organization (WHO)
International Standard for human parvovirus B19 (B19) DNA nucleic acid amplifica-
tion techniques (NAT).
 
Materials and methods
 
Four samples: AA, BB (which were lyophilized), CC and DD
(which were liquid preparations) were analysed using several different NAT assays.
The mean B19 DNA content of each sample was determined for each laboratory using
an end-point dilution method.
 
Results
 
There was good agreement between the overall mean ‘equivalents’/ml
obtained by the different assays. The mean log
 
10
 
 ‘equivalents’/ml were 5·76 for sample
AA, 5·73 for sample BB, 5·82 for sample CC and 7·70 for sample DD. The differences
in titre among samples AA, BB and CC were not statistically significant, but the titre
of DD was significantly higher.
 
Conclusions
 
Despite the range of NAT assays used in the study, it was possible to
calculate the mean B19 DNA concentrations in the four preparations. Lyophilized
preparation AA was established as the first International Standard for B19 DNA NAT
assays and was assigned a concentration of 10
 
6
 
 international units (IU)/ml.
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Introduction
 
Human parvovirus B19 (B19) causes erythema infectiosum
(EI), transient aplastic crisis in patients with haemolytic
anaemia (TAC), and has been associated with fetal death,
arthritis and chronic anaemia [1]. B19 is a common infection
in humans and most people become infected during their
lifetime (
 
»
 
 40–60% of adults over 20 years of age have anti-
bodies to B19) [2]. The majority of plasma pools used to prepare
blood products have been shown to be contaminated with
B19 sequences [3,4]. B19 is non-enveloped and thermostable
and therefore difficult to inactivate by the standard inactiva-
tion methods (solvent–detergent, pasteurization) that are
used during the manufacture of blood products. Recent
studies have shown that B19 DNA sequences are present in
a range of blood products [5,6]. Although B19 is normally
spread via the respiratory route, parenteral transmission can
occur through the administration of blood products made
from plasma pools contaminated with B19 [7–9]. Despite
the presence of antibodies to B19 in all plasma pools, some
products made from contaminated pools have been recently
reported [9] to transmit B19 as a result of the high viral
load.
Reducing the levels of B19 by screening plasma minipools
for B19 DNA may be necessary in order to minimize the
potential risk of transmission and improve the margin of
safety of products used to treat, for example, immunocom-
promised individuals, haemophiliacs and pregnant women.
Diagnosis of B19 is based on the detection of specific immuno-
globulin M (IgM) or immunoglobulin G (IgG) antibodies
[2,10], nucleic acid hybridization assays [11], or, more
recently, nucleic acid amplification technology (NAT) assays
[12]. The most sensitive assay for detecting B19 in plasma
pools, where the virus may be present in low concentrations,
is NAT. However, NAT assays vary widely in sensitivity and
specificity and the use of a well-calibrated standard is essen-
tial for comparison of data and the routine introduction of
such assays. A working reagent for B19 NAT assays has been
available since 1997 [13] but there is a need for an Inter-
national Standard that can be used to calibrate secondary
standards and to validate and calibrate assays.
The first World Health Organization (WHO) International
Standard for NAT assays was established in 1997 for hepatitis
C virus (HCV) RNA assays [14] and was essential for the intro-
duction of routine screening of blood donations and plasma
pools for HCV RNA by NAT assays. In 1999, two further WHO
International Standards for hepatitis B virus (HBV) DNA and
human immunodeficiency virus-1 (HIV-1) RNA assays were
established [15,16]. The objectives of the present study were
to assess the suitability of candidate preparations as the WHO
International Standard for B19 DNA for use in NAT assays
and to determine the B19 DNA content of the candidate
standard.
 
Materials and methods
 
Participants
 
Results were returned by 26 laboratories (reference laboratories,
blood product manufacturers, kit manufacturers, regulatory
laboratories and research laboratories) from 14 different
countries. Each laboratory was allocated a random code number.
 
Preparation and evaluation of candidate materials
 
Four candidate materials were included in the study: samples
AA and BB were lyophilized preparations and samples CC and
DD were liquid preparations. Materials AA and BB were prepared
by diluting a positive donation, containing 
 
»
 
 2 
 
·
 
 10
 
12
 
 genome
equivalents/ml (geq/ml), 10
 
6
 
-fold in 2·5 l of pooled plasma.
Sample CC (B19 DNA concentration 
 
»
 
 10
 
6
 
 geq/ml) was pre-
pared by the Center of Biologics Evaluation and Research
(CBER) (Bethesda, MD) by diluting a positive donation in pooled
plasma. Sample DD (B19 DNA concentration 
 
»
 
 10
 
7
 
–10
 
8
 
 geq/
ml) was prepared at the Central Laboratory of the Netherlands
Blood Transfusion Service (CLB) (Amsterdam, the Nether-
lands) by diluting a positive donation in pooled plasma. All
diluents were negative for HBV DNA, B19 DNA, HCV RNA
and HIV RNA, and negative for antibodies to B19, hepatitis B
surface antigen (HBsAg), HCV and HIV, except the diluent used
to prepare AA and BB which was positive for antibodies to B19.
 
Lyophilization of samples AA and BB
 
Lyophilization of the material was performed as previously
described for the HCV [14] and HBV [15] candidate Inter-
national Standards. The coefficient of variation of the fill volume
was 0·63% and 0·71% for samples AA and BB, respectively.
 
Design of the study
 
Participants were sent four vials of each material and requested
to perform four independent assays (for B19 DNA) of the four
samples on different days. For each assay, dilutions of all four
candidate materials (prepared in the sample diluent normally
used in the assay system) were to be tested concurrently so that
the B19 DNA content of each preparation could be determined.
The first assay of the four candidate materials was performed
using 10-fold dilutions of the preparations in order to deter-
mine the B19 DNA end-point of each preparation, while the
remaining three assays were carried out on half-log dilutions
(i.e. 1 : 3·3 dilutions) on either side of the determined end-points.
 
Statistical methods
 
The statistical methods used for this study were identical to
those used in previous collaborative studies to establish
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International Standards for HCV RNA [14] and HBV DNA
[15]. The relative potencies were calculated as the differences
in estimated log
 
10
 
 polymerase chain reaction (PCR) detectable
units/ml, and the statistical significance of differences
between samples was assessed using paired 
 
t
 
-tests.
Qualitative assays were analysed as previously described
[14,15]. Briefly, for each laboratory and assay method, data
from all assays were pooled to give the number positive out of
the number tested at each dilution step. A single ‘end-point’
for each such dilution series was calculated by the method of
maximum likelihood, using the statistical package 
 
GLIM
 
 [17].
The calculated end-point was used to give an estimated number
of ‘detectable units/ml’ after correcting for the equivalent
volume of the test sample. The estimates, referred to as ‘PCR
detectable units/ml’, are not necessarily directly equivalent
to a genuine copy number/ml or genome equivalent/ml.
Duplicate test results, where reported in an assay, were
treated as if from independent assays.
For quantitative assays, a single estimate was obtained for
each sample (by calculating the mean of repeat estimates
within a single assay after correcting for sample dilution),
and estimates for all assays were used to calculate overall
mean estimates for individual laboratories.
 
Accelerated degradation studies on sample AA
 
Vials of sample AA were incubated at +4 
 
°
 
C, +20 
 
°
 
C, +37 
 
°
 
C
and +45 
 
°
 
C, and duplicate vials were removed, as shown in
Table 1, and stored at –20 
 
°
 
C until analysis. For comparison,
vials stored at –20 
 
°
 
C were extracted and amplified in paral-
lel. For analysis, the vials were thawed and the contents
redissolved in 0·5 ml of DNAse-free water for 20 min at room
temperature. It was not possible to redissolve the contents of
vials incubated at +45 
 
°
 
C for 3 weeks or longer.
B19 DNA was extracted from 200 
 
m
 
l of samples using the
Qiagen DNA mini kit (Qiagen, Hilden, Germany). Briefly,
the samples were dissolved in a proteinase K/guanidinium
buffer, the nucleic acids bound to a silica filter, washed to
remove contaminants and eluted in 60 
 
m
 
l of water. For PCR
analysis, 10 
 
m
 
l of sample was amplified in a LightCycler
(Roche Molecular Biochemicals, Mannheim, Germany).
 
PCR amplification
 
Log
 
10
 
 dilutions of the samples were prepared in diluent
(10 ng/ml tRNA in water) and amplified using the Roche
LightCycler system. The samples were amplified in two
batches. For each batch of samples, duplicate vials of AA,
stored at –20 
 
°
 
C, were amplified in parallel. In order to cal-
culate the titres, a standard curve was constructed for each
experiment. For the standard curve, log
 
10
 
 dilutions of the two
samples stored at –20 
 
°
 
C were prepared and amplified. The
titre of the undiluted material was taken as 10
 
6
 
 IU/ml. For the
test samples, 10
 
–1
 
 and 10
 
–2
 
 dilutions were assayed.
 
Results
 
Assays
 
All laboratories returned data from qualitative assays. Labor-
atory 8 returned data from two different assay methods, and
the results are reported separately (8A and 8B). Laboratories
16 and 18 used two different extraction methods, and the
results are reported separately (16A, 16B, 18A and 18B). Two
laboratories (2 and 19) returned data from quantitative
assays in addition to their qualitative results, while labor-
atory 12 provided qualitative and quantitative data from
the same set of assays. All the quantitative assays were based
on TaqMan real-time PCR using the ABI Prism 7700 (Applied
Biosystems, Foster City, CA) and the results are reported
separately (02Q, 12Q and 19Q). The overall results are there-
fore based on a maximum of 32 data sets (‘laboratories’). All
laboratories used in-house PCR assays, with a single primer
pair or nested primers from the NS1, VP1 or VP2 regions.
Laboratory 8 used a commercial assay (8B; SMI Test, Genome
Science Laboratory Co. Ltd, Japan).
For B19 DNA extraction, the majority of laboratories used
common commercial extraction kits such as the QIAamp
viral RNA and DNA blood or mini kits (Qiagen) and the Nucli-
sens kit (both manual and automated) (Organon Teknika,
Boxtel, the Netherlands). Other commercial kits used were
the Roche/Boehringer High Pure Template preparation kit
(Penzberg, Germany) (laboratory 1), the Watson kit (laboratory
10) and the SMI test (Genome Science Laboratory Co. Ltd)
(laboratories 8 and 26). Several laboratories used proteinase
K/sodium dodecyl sulphate (SDS) digestion followed by
phenol–chloroform extraction or heat inactivation, while
two laboratories, 14 and 21, used sodium iodide extraction
and laboratory 17 used NaOH extraction followed by neutral-
ization with HCl. Laboratories 9 and 18 used a chaotropic
agent followed by absorption onto silica.
 
Estimates of PCR detectable units/ml or geq/ml
 
The estimates of PCR detectable units/ml obtained from the
Table 1 Calculated mean titres (log10 IU/ml) of the samples in the 
accelerated degradation study compared with the titre of the candidate 
standard AA (stored at –20 ° C)
Incubation time
Incubation temperature
–20 ° °°° C +4 ° °°° C +20 ° °°° C +37 ° °°° C +45 ° °°° C
1 week 6·0 5·9 5·9
4 weeks 6·0 6·1 5·9 6·1 –
8 weeks 6·0 6·1 –
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qualitative assays, and the estimates of geq/ml obtained from
the quantitative assays, are shown in histogram form in
Fig. 1(a–d) for samples AA to DD, respectively. Each box rep-
resents the estimate from one laboratory and/or method and
is labelled with the laboratory code number. In some cases, it
was not possible to calculate results using the Poisson model
owing to inconsistent results for a particular dilution series
(sample BB, laboratory 9) or because of dilution errors, which
resulted in all samples in a dilution series being positive or
negative (sample DD, laboratories 21 and 23).
The majority of laboratories had estimates that were within
a range of 2·0 log
 
10
 
 for each sample. However, results from
some laboratories (laboratory 21, samples AA and DD; and
laboratory 17, samples AA and BB) were lower than the
majority of results. The overall means for each sample are
given in Table 2, along with the standard deviation and range
of estimates between laboratories. For laboratories that fol-
lowed the recommended layout for the qualitative assays,
95% confidence intervals for an individual laboratory esti-
mate were 
 
»
 
 0·5 log
 
10
 
–0·8 log
 
10
 
 PCR detectable units/ml in
overall width. This reflects the degree of uncertainty inherent
in any laboratory estimate and should be borne in mind when
comparing results between laboratories. The shape of the dis-
tribution of estimates for sample CC and, to a lesser extent,
sample DD, appeared bimodal, with a group of laboratories
obtaining similar estimates that were lower than those of
the majority of laboratories. It is not clear whether this could
be the result of the different assay methods having different
Fig. 1 Laboratory estimates of log10 polymerase 
chain reaction (PCR) detectable units or genome 
equivalents/ml for: (a) sample AA; (b) sample BB; 
(c) sample CC; and (d) sample DD.
 
VOX_132.fm  Page 27  Tuesday, December 18, 2001  10:19 AM
 28
 
J. Saldanha 
 
et al.
 
©
 
 2002 Blackwell Science Ltd. 
 
Vox Sanguinis
 
 (2002) 
 
82
 
, 24–31
 
sensitivities to sample CC, or whether it was simply a result
of individual assay variability.
 
Relative potencies
 
The potencies of samples BB, CC and DD obtained for each
laboratory were expressed relative to sample AA and are
shown in Fig. 2(a–c), respectively. The overall means, along
with standard deviations and ranges, are given in Table 3.
However, the variation between laboratories has only been
reduced slightly, reflecting the considerable assay variability
inherent in the qualitative assays used in this study. The
shape of the distribution of relative potencies for sample CC
(Fig. 2b) does not exhibit the bimodal shape noted above for
the distribution of direct estimates of ‘units’/ml (Fig. 1c), sug-
gesting that there is not a different sensitivity to sample CC
between assay methods.
 
Accelerated degradation studies
 
As duplicate samples were assayed at each time-point for
each temperature, four sets of data were obtained for each
time point/temperature, except for samples incubated for
4 weeks at +4 
 
°
 
C and for 1 week at +45 
 
°
 
C. The calculated
mean concentrations (IU/ml) for each time-point/temper-
ature are shown in Table 1. The results indicated that AA was
stable at +4 
 
°
 
C and +20 
 
°
 
C for at least 4 weeks and at +37 
 
°
 
C
for at least 8 weeks. The sample was also stable at +45 
 
°
 
C for
Fig. 1 Continued
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Fig. 2 Potency (in log10 units) of: (a) 
BB relative to AA; (b) CC relative to 
AA; and (c) DD relative to AA. 
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1 week, but analysis of material incubated at +45 
 
°
 
C for
longer than 1 week was not possible owing to the insolubility
of the material.
 
Discussion
 
The WHO has established clear guidelines for the develop-
ment of International Standards. Two requirements are par-
ticularly important: International Standards should be stable,
lyophilized materials; and laboratories from as many coun-
tries as possible should be allowed to participate in the develop-
mental process. Clearly, some participating laboratories
will not be as proficient as other laboratories. The aim of the
study, however, is to determine whether the candidate mater-
ial can be assayed by different assays in several laboratories
and then to assign a potency to the material. While this
should be as close to its concentration a possible, it is not the
aim to obtain an accurate figure for the concentration of the
material. The agreed standard will then be used by labor-
atories to validate and standardize their assay methods.
In this study there was good agreement between the over-
all mean ‘detectable’ units/ml obtained by all participants,
except for laboratories 17 and 21. However, omitting results
from these laboratories made little difference to the overall
mean estimates for the four candidate samples (Table 2) and
results from all laboratories were included for the final over-
all mean estimates. Sample AA (code 99/800) was accepted
as the first WHO International Standard for human parvo-
virus B19 DNA NAT assays by the WHO Expert Committee
on Biological Standardization (ECBS) at their meeting in
November 2000. The proposed assigned potency of this
material is 10
 
6
 
 IU/ml and each vial of the International Stand-
ard contains 5 
 
·
 
 10
 
5
 
 IU. Using the calculated mean titres for
sample AA (Table 2), the ratio of IU: PCR detectable units is
1: 0·6–0·8. However, if the data from only the quantitative
assays (2Q, 12Q and 19Q) are used, the ratio is 1: 2 (IU:
genome equivalents).
Despite B19 infection being of short duration with mild
clinical symptoms in the majority of cases, many blood prod-
uct manufacturers have begun screening for B19 by NAT in
plasma minipools [18]. Unlike HCV RNA screening of pools
where all positive donations are removed from the manu-
facturing pool, B19 DNA screening is aimed at reducing the level
of B19 DNA in the manufacturing pool and not eliminating
all positive donations, as this would lead to unacceptably
high losses of plasma. A common strategy is to test donations
in minipools and remove all donations with titres > 10
 
6
 
 geq/
ml [18]. Removal of such donations results in manufacturing
pools containing < 10
 
4
 
 geq/ml. Preliminary results indicate
that products made from screened pools are negative for
B19 DNA. Data derived from studies with solvent–detergent
treated pooled plasma [9] have suggested that B19 transmis-
sions were associated with product lots having high levels of
B19 DNA but not with those having < 10
 
4
 
 geq/ml. At present,
there are no mandatory requirements for B19 DNA screening.
However, in the USA, the Blood Products Advisory Commit-
tee (BPAC) concluded at the 1999 BPAC meeting that NAT for
B19 would be considered by the Food and Drug Administra-
tion (FDA) to be an ‘in-process’ control rather than a donor
Table 2 Overall mean estimates (log10 ‘equivalents’/ml) for the four 
candidate samples
Sample 
(data set)a Mean
Standard 
deviation Minimum Maximum Range
AA
1 5·76 0·80 2·73 6·72 3·99
2 5·86 0·58 3·92 6·72 2·80
3 5·92 0·47 4·84 6·72 1·88
BB
1 5·73 0·63 3·92 6·85 2·93
2 5·76 0·62 3·92 6·85 2·93
3 5·82 0·52 4·78 6·85 2·07
CC
1 5·82 0·58 4·69 6·90 2·21
2 5·85 0·55 4·79 6·90 2·11
3 5·89 0·53 4·79 6·90 2·11
DD
1 7·70 0·66 6·10 9·08 2·98
2 7·75 0·60 6·50 9·08 2·58
3 7·78 0·51 6·50 9·08 2·58
aData sets: 1, all laboratories; 2, excluding laboratory 21; 3, excluding 
laboratories 17 and 21.
Table 3 Overall mean potencies of samples BB, CC and DD relative to sample 
AA (log10 ‘units’/ml)
Sample 
(data set)a Mean
Standard 
deviation Minimum Maximum Range
BB
1 –0·04 0·55 –1·41 2·01 3·42
2 –0·11 0·41 –1·41 0·64 2·05
3 –0·11 0·42 –1·41 0·64 2·05
CC
1 0·06 0·62 –1·50 1·95 3·45
2 –0·00 0·52 –1·50 1·00 2·50
3 –0·04 0·49 –1·50 1·00 2·50
DD
1 1·94 0·55 0·88 3·37 2·49
2 1·89 0·48 0·88 3·00 2·12
3 1·85 0·44 0·88 2·91 2·03
aData sets: 1, all laboratories; 2, excluding laboratory 21; 3, excluding 
laboratories 17 and 21.
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screening test. Consequently, blood product manufacturers
would only be required to validate the assay in terms of
sensitivity, specificity and reproducibility, and would not be
required to perform clinical trials for assay validation. The
proposed FDA limit for manufacturing pools, based on B19
transmission by solvent–detergent pooled plasma [19,20], is
< 10
 
4
 
 geq/ml. The use of B19 NAT as a limit test to control
the amount of virus in plasma pools requires the availability
of well-calibrated standards in order to define and measure
these limits. The establishment of an International Standard
for B19 NAT assays would provide such a reagent.
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